Todd Neale

I will not be using this account moving forward. Find me at the same handle over on Bluesky.

A new #JACC study evaluates repeat rejection after pediatric #Hearttx, finding that while it occurs less often, it remains a risk factor for graft loss. @ToddNeale reports on the findings in @TCTMD: bit.ly/3YqFmfU #cvPed

tctmd.com/news/cardiovas… "Warfare is the antithesis of global health. . . . Health and peace go hand in hand". @ToddNeale @TCTMD @ehj_ed @escardio @ESC_Journals @FrancescoPaneni @AlhijjiM

Breast artery calcification is linked with worse CV outcomes in women, according to a new study in #JACCAdvances. Learn more with @TCTMD: bit.ly/40eQor9 @ToddNeale #CardioX

The #1 reason for GDMT underuse in #HFrEF patients is clinical inertia, according to a research letter in #JACCHF. @ToddNeale discusses the findings in @TCTMD: bit.ly/4gzgTgt

Commenting to @ToddNeale, ACC VP @ChrisKramerMD, said Tri.Fr adds “to the amount of evidence that suggests that one can palliate TR with edge-to-edge repairs and improve QoL and the ability to do activities of daily living." bit.ly/4dJrlA1 #ESCCongress

SHAM-PVI: Catheter Ablation Improves Objective Measure of AF Burden #ESCCongress tctmd.com/news/sham-pvi-…

A new analysis finds renal denervation using radiofrequency energy is cost-effective, high-value intervention for patients with uncontrolled #hypertension. @TCTMD's @ToddNeale reports: bit.ly/4g400Kv

ACC has updated its expert consensus decision pathway for patients hospitalized with #HeartFailure. The updated guidance is published in #JACC. Get the details: bit.ly/4dIerls @TCTMD @ToddNeale

Congratulations to Dr Yang and the study authors for important new insights for ACS prediction by #YesCCT at #SCCT2024 @Heart_SCCT!! …Choi said, the study “does show us that it's integrative analysis—it's the combination of stenosis, quantitative plaque burden, and flow—that moves the needle…” Looking forward to further studies and work from this group and the field as #YesCCT moves closer to achieving the “Holy Grail” of Cardiology through #AI/ML analysis for our patients @TCTMD @iamritu @DavidJHur1 @ChinnaiyanMD @CardiacCTGuy @onco_cardiology

Whether the presence of coronary calcium should be routinely included on noncardiac CT scan reports was debated at #SCCT2024 by @MichaelJBlaha and @MBittencourtMD @Heart_SCCT @TCTMD tctmd.com/news/should-co…

"It adds another layer in us being able to initiate this therapy with a little more precision," @AlexRazavi says; comments from @CardiacCTGuy #SCCT2024 tctmd.com/news/coronary-…

Excited to see the future of @Heart_SCCT as #yescct use grows. How will we achieve equitable healthcare delivery? @iamritu @DavidJHur1 @OKhaliqueMD @CardiacCTGuy @ToddVillinesMD @purviparwani @ACCinTouch @ChrisKramerMD

"This highlights the critical role of coronary inflammation as a potential therapeutic target in cardiovascular prevention," Kenneth Chan says #SCCT2024; commentary from @ChinnaiyanMD tctmd.com/news/coronary-…

Thanks to @DrM_ODonoghue @DLBHATTMD @_WayneBatchelor @ACCmediacenter @ACCinTouch for their help on this @TCTMD tctmd.com/news/fda-add-n…

“I think internationally we have a collective responsibility to help this part of the world.” Prof Craig Anderson talks to @ToddNeale from @TCTMD about the under-representation of Asia-Pacific in cardiovascular clinical trials. bit.ly/4cSiMlK

"Despite the fact that a lion’s share of the burden of disease is going to be where the population is, we don’t tend to perform trials in this region or enroll as many patients from this region," @ProfSNicholls says; @dukwoo_park, Craig Anderson weigh in tctmd.com/news/going-glo…

"Some of this, I believe, is a reasonable use, a medically justifiable use. But I do believe that there is definitely a proportion of these patients who do not need to be on a daily preventive aspirin," @MohakGuptaMD says @TCTMD tctmd.com/news/aspirin-p…

Discussing post-LAAO leaks and what to do about them at #NYValves2024 with @DrTomWaggoner @VivekReddyMD & Robert Sommer @TCTMD tctmd.com/news/leaks-aft…

Although there was no significant difference in all-cause mortality between the DOAC and VKA groups at 1 year, a significant difference had emerged by 3 years and widened by 5 years, @AgamBansal5 reports #NYValves2024 @JimmyStewart00 @TCTMD tctmd.com/news/long-term…